Arthneeti

Haleos Labs Share Price & Earnings Call Analysis

₹1,397.90-1.90% today
Market cap
₹423 Cr
P/E
26.73
ROE
8.44%
PEG
1.30
Price to sales
1.30
Debt to equity
0.52
52W high / low
₹1,690 / ₹1,126
Sales growth (5Y)
4.68%
EBITDA margin
12.62%
Net profit margin
5.33%
Promoter holding
72.11%
Sales (last year)
₹324 Cr

Incorporated in 2006, SMS Lifesciences Ltd is in the business of manufacturing of Active Pharma Ingredients and their intermediates[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Haleos Labs Limited rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Haleos Labs Limited.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Haleos Labs Limited

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Haleos Labs Limited

Quarterly Results

Quarter-by-quarter operating performance

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales +88.2963.7374.6569.2672.0589.9992.5578.4684.6089.1182.5081.3794.78
Expenses +78.9261.4572.1161.3362.7578.6376.2769.8971.8581.6970.7967.7980.73
Operating Profit9.372.282.547.939.3011.3616.288.5712.757.4211.7113.5814.05
OPM %10.61%3.58%3.40%11.45%12.91%12.62%17.59%10.92%15.07%8.33%14.19%16.69%14.82%
Other Income +0.494.810.610.270.582.360.442.040.062.341.000.420.18
Interest1.671.802.182.812.342.842.402.142.142.031.871.621.54
Depreciation2.632.923.703.733.733.783.683.763.763.803.823.893.91
Profit before tax5.562.37-2.731.663.817.1010.644.716.913.937.028.498.78
Tax %31.29%10.55%40.29%126.51%-8.14%8.73%33.27%29.72%29.81%11.45%37.61%24.38%24.26%
Net Profit +3.822.11-3.83-0.444.126.477.103.304.863.484.396.426.65
EPS in Rs13.205.66-5.952.2514.2219.5223.1515.4518.099.8213.7620.1821.90

Financials of Haleos Labs Limited

Profit & Loss

Annual income statement trend

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales +378261266350316306345348
Expenses +343235235316287275300301
Operating Profit3525303529314547
OPM %9%10%11%10%9%10%13%13%
Other Income +222145454
Interest655671097
Depreciation6881011151515
Profit before tax2515203317102628
Tax %30%31%31%23%31%36%28%
Net Profit +181014251161921
EPS in Rs59.0433.6744.8583.7537.9130.0766.5265.66
Dividend Payout %3%0%3%2%4%5%2%

Financials of Haleos Labs Limited

Balance Sheet

Capital structure and asset base

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital33333333
Reserves103113126149166174194203
Borrowings +476565801001018670
Other Liabilities +11672108125126114107118
Total Liabilities270253302357395391390394
Fixed Assets +118124130142228223232226
CWIP31638511609
Investments00000000
Other Assets +148113134164166162158159
Total Assets270253302357395391390394

Financials of Haleos Labs Limited

Cash Flows

Operating, investing and financing cash movement

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +301535-11152434
Cash from Investing Activity +-44-27-26-7-31-18-15
Cash from Financing Activity +1512-31117-7-19
Net Cash Flow1-06-80-1-0
Free Cash Flow6-9-0-53-28419
CFO/OP105%69%133%-10%62%88%94%

Financials of Haleos Labs Limited

Ratios

Working capital efficiency and return ratios

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days40304735536173
Inventory Days116149164159184196160
Days Payable140101163146127143126
Cash Conversion Cycle16784848110115106
Working Capital Days141821724117
ROCE %12%13%12%8%7%12%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals